Aerpio Pharmaceuticals, Inc. (ARPO)
| Market Cap | 49.68M |
| Revenue (ttm) | 15.00M |
| Net Income (ttm) | -4.32M |
| Shares Out | 42.62M |
| EPS (ttm) | -0.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $1.05 |
| Previous Close | $1.05 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 1.07 |
| Day's Range | 1.04 - 1.10 |
| Day's Volume | 593,114 |
| 52-Week Range | 0.57 - 2.31 |
Aerpio Pharmaceuticals (ARPO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Aerpio Pharmaceuticals, Inc. (ARPO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CINCINNATI, March 11, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 in ...
Quantum Leap Healthcare Collaborative-sponsored I-SPY COVID Trial will not further test Aerpio Pharmaceuticals Inc's (NASDAQ: ARPO) razuprotafib. Razuprotafib was chosen because it was believed to stabi...
SAN FRANCISCO and CINCINNATI, March 05, 2021 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, will not proceed with further testing of the Aerpio P...
Aerpio (ARPO) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.
Aerpio (ARPO) unveils strategic alternatives after it announced top-line results from a phase II study of razuprotafib in glaucoma patients in December.
Aerpio Pharmaceuticals (ARPO) has been struggling lately, but the selling pressure may be coming to an end soon.
CINCINNATI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2, tod...
Does Aerpio Pharmaceuticals, Inc. (ARPO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific upd...
Primary endpoint achieved with twice-daily dose group at 28 day time point versus latanoprost control group.
Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors.
Aerpio Pharmaceuticals, Inc. (ARPO) Management on Q3 2020 Results - Earnings Call Transcript
Conference Call Today, November 10 , 2020 at 8:30 a.m. EST
CINCINNATI, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disea...
Call Taking Place on Thursday, November 12th @ 11amET Call Taking Place on Thursday, November 12th @ 11amET
The trial in moderate-to-severe patients is Aerpio's second clinical trial in COVID-19 patients and is funded in part by the U . S . military
Topline Data Expected 4Q 2020 Topline Data Expected 4Q 2020
SAN FRANCISCO and CINCINNATI, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today dosing...
Aerpio Pharmaceuticals' (ARPO) Management on Q2 2020 Results - Earnings Call Transcript
Conference Call Today, August 12, 2020 at 8:30 a.m. EDT
CINCINNATI, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular dis...
CINCINNATI, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and The U.S. Government operating through the Medical Technology Enterprise Consortium (MTEC) annou...
In the latest trading session, Aerpio Pharmaceuticals, Inc. (ARPO) closed at $1.26, marking a +1.61% move from the previous day.
Is (ARPO) Outperforming Other Medical Stocks This Year?
As of late, it has definitely been a great time to be an investor in Aerpio Pharmaceuticals.
Aerpio Pharmaceuticals, Inc. (ARPO) closed the most recent trading day at $1.25, moving +0.81% from the previous trading session.
Top Ranked Momentum Stocks to Buy for June 19th
Is (ARPO) Outperforming Other Medical Stocks This Year?
CINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ARPO), today announced that, due to the public health and safety concerns related to the novel coron...
CINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular dis...
SAN FRANCISCO and CINCINNATI, May 27, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agree...
SAN FRANCISCO and CINCINNATI, May 27, 2020 /PRNewswire/ -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agreement h...
Aerpio Pharmaceuticals, Inc. (ARPO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
Aerpio Received an Immediate Payment of $15 million Aerpio Received an Immediate Payment of $15 million
Aerpio Pharmaceuticals, Inc. (ARPO) closed at $0.72 in the latest trading session, marking a +0.61% move from the prior day.
Is (ARPO) Outperforming Other Medical Stocks This Year?
Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Aerpio Pharmaceuticals, Inc. (ARPO) on Q4 2019 Results - Earnings Call Transcript
Our year-end roundtable rolls into 2020 with a look at small-cap investing.
Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Shares of Aerpio Pharmaceuticals Inc. plummeted 71% toward a record low in active trade Monday, after the biopharmaceutical company said a phase 2b study of its treatment for diabetic retinopathy failed...
About ARPO
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hyp... [Read more...]
| Industry Biotechnology | |
| Stock Exchange NASDAQ | Ticker Symbol ARPO |
Analyst Forecasts
According to 2 analysts, the average rating for ARPO stock is "Buy." The 12-month stock price forecast is 1.75, which is an increase of 66.67% from the latest price.